Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Functional antibodies as immunological endpoints to evaluate protective immunity against Shigella.

Ndungo E, Pasetti MF.

Hum Vaccin Immunother. 2019 Aug 1:1-9. doi: 10.1080/21645515.2019.1640427. [Epub ahead of print]

PMID:
31287754
2.

A Novel Shigella Proteome Microarray Discriminates Targets of Human Antibody Reactivity following Oral Vaccination and Experimental Challenge.

Ndungo E, Randall A, Hazen TH, Kania DA, Trappl-Kimmons K, Liang X, Barry EM, Kotloff KL, Chakraborty S, Mani S, Rasko DA, Pasetti MF.

mSphere. 2018 Aug 1;3(4). pii: e00260-18. doi: 10.1128/mSphere.00260-18.

3.

A Single Residue in Ebola Virus Receptor NPC1 Influences Cellular Host Range in Reptiles.

Ndungo E, Herbert AS, Raaben M, Obernosterer G, Biswas R, Miller EH, Wirchnianski AS, Carette JE, Brummelkamp TR, Whelan SP, Dye JM, Chandran K.

mSphere. 2016 Mar 30;1(2). pii: e00007-16. doi: 10.1128/mSphere.00007-16. eCollection 2016 Mar-Apr.

4.

Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies.

Bornholdt ZA, Ndungo E, Fusco ML, Bale S, Flyak AI, Crowe JE Jr, Chandran K, Saphire EO.

MBio. 2016 Feb 23;7(1):e02154-15. doi: 10.1128/mBio.02154-15.

5.

Filovirus receptor NPC1 contributes to species-specific patterns of ebolavirus susceptibility in bats.

Ng M, Ndungo E, Kaczmarek ME, Herbert AS, Binger T, Kuehne AI, Jangra RK, Hawkins JA, Gifford RJ, Biswas R, Demogines A, James RM, Yu M, Brummelkamp TR, Drosten C, Wang LF, Kuhn JH, Müller MA, Dye JM, Sawyer SL, Chandran K.

Elife. 2015 Dec 23;4. pii: e11785. doi: 10.7554/eLife.11785.

6.

Novel Small Molecule Entry Inhibitors of Ebola Virus.

Basu A, Mills DM, Mitchell D, Ndungo E, Williams JD, Herbert AS, Dye JM, Moir DT, Chandran K, Patterson JL, Rong L, Bowlin TL.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S425-34. doi: 10.1093/infdis/jiv223. Epub 2015 Jul 22.

7.

Cell entry by a novel European filovirus requires host endosomal cysteine proteases and Niemann-Pick C1.

Ng M, Ndungo E, Jangra RK, Cai Y, Postnikova E, Radoshitzky SR, Dye JM, Ramírez de Arellano E, Negredo A, Palacios G, Kuhn JH, Chandran K.

Virology. 2014 Nov;468-470:637-646. doi: 10.1016/j.virol.2014.08.019. Epub 2014 Oct 11.

8.

Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.

Lennemann NJ, Rhein BA, Ndungo E, Chandran K, Qiu X, Maury W.

MBio. 2014 Jan 28;5(1):e00862-13. doi: 10.1128/mBio.00862-13.

9.

A mutation in the Ebola virus envelope glycoprotein restricts viral entry in a host species- and cell-type-specific manner.

Martinez O, Ndungo E, Tantral L, Miller EH, Leung LW, Chandran K, Basler CF.

J Virol. 2013 Mar;87(6):3324-34. doi: 10.1128/JVI.01598-12. Epub 2013 Jan 9.

10.

Niemann-Pick C1 (NPC1)/NPC1-like1 chimeras define sequences critical for NPC1's function as a flovirus entry receptor.

Krishnan A, Miller EH, Herbert AS, Ng M, Ndungo E, Whelan SP, Dye JM, Chandran K.

Viruses. 2012 Oct 25;4(11):2471-84. doi: 10.3390/v4112471.

11.

Ebola virus entry requires the host-programmed recognition of an intracellular receptor.

Miller EH, Obernosterer G, Raaben M, Herbert AS, Deffieu MS, Krishnan A, Ndungo E, Sandesara RG, Carette JE, Kuehne AI, Ruthel G, Pfeffer SR, Dye JM, Whelan SP, Brummelkamp TR, Chandran K.

EMBO J. 2012 Apr 18;31(8):1947-60. doi: 10.1038/emboj.2012.53. Epub 2012 Mar 6.

12.

Foxa2 activity increases plasma high density lipoprotein levels by regulating apolipoprotein M.

Wolfrum C, Howell JJ, Ndungo E, Stoffel M.

J Biol Chem. 2008 Jun 13;283(24):16940-9. doi: 10.1074/jbc.M801930200. Epub 2008 Apr 1.

13.

Mechanisms and optimization of in vivo delivery of lipophilic siRNAs.

Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, Rajeev KG, Nakayama T, Charrise K, Ndungo EM, Zimmermann T, Koteliansky V, Manoharan M, Stoffel M.

Nat Biotechnol. 2007 Oct;25(10):1149-57. Epub 2007 Sep 16.

PMID:
17873866

Supplemental Content

Loading ...
Support Center